乳腺癌耐药蛋白在急性髓性白血病中的表达和临床意义

The Gene Expression and It's Clinical Significance of Breast Cancer Resistance Protein(BCRP) in Patients with Acute Non-lymphocytic Leukemia(AML)

目的探讨急性髓性白血病(AML)患者乳腺癌耐药蛋白(BCRP)的表达与临床耐药的关系。方法应用半定量反转录-聚合酶链反应(RT-PCR),以MCF7乳腺癌细胞株、HL60白血病细胞株分别作为BCRP及MDR1 mRNA表达的参照标准,以β肌动蛋白(-βactin)为内对照,检测了54例AML患者BCRP mRNA的表达,其中8例患者测定MDR1 mRNA的表达,初步探讨BCRP表达在AML中的临床意义。结果AML中BCRP mRNA表达水平差异较大,BCRP表达由低到高依次为对照组、完全缓解组、初治敏感组和临床耐药组。其中临床耐药组BCRP阳性率显著高于对照组及完全缓解组,差异有统计学意义(P<0.01及P<0.05),BCRP表达与MDR1表达无相关性(P>0.05)。结论BCRP在AML中表达水平差异较大,与MDR1的表达无关,可能是AML患者临床耐药的一个独立的重要原因,是预后的不利因素。

Objective To investigate the relationship between the expression of BCRP gene and drug resistance in patients with AML. Methods The expression of BCRP gene in 54 AML and multidrug resistence transporter P-glycoprotein（MDR1） gene in 8 AML patients were examined by semiquantitative reverse transcriptase-polymerase chain reaction （RT-PCR）. MCF7 cell lines and HL60 cell lines were used as reference standard for BCRP and MDR1 respectively. β-actin were used as the internal control. Results The positivity rate of BCRP gene expressed in patients with AML was high. The variation of expression level was observed. The magnitude order of expression level was as follows： the control group, complete remission（CR） group, newly diagnosed/drug-sensitive group and relapsed group. The expression level of BCRP mRNA and the positive rate of BCRP in relapased group was significantly higher than that in the control group and in the CR group （P 〈 0.01 and P 〈 0.05 respectively）. Conclusion AML patients are of elevated expression of BCRP gene which are no linear relation with that of MDR1. The excessive expression of that might induce drug resistance and might be an Unfavorable factor for AML patients.